The Potential Role of Bacteriophages in the Treatment of Recalcitrant Chronic Rhinosinusitis

Chronic rhinosinusitis is a common condition affecting 5–12% of the general population worldwide. In a limited number of cases, the disease is recalcitrant to medical and surgical interventions, causing a major impact on physical, social and emotional well-being and increasing pressure on healthcare...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Saartje Uyttebroek [verfasserIn] Jolien Onsea [verfasserIn] Willem-Jan Metsemakers [verfasserIn] Lieven Dupont [verfasserIn] David Devolder [verfasserIn] Jeroen Wagemans [verfasserIn] Rob Lavigne [verfasserIn] Isabel Spriet [verfasserIn] Laura Van Gerven [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	chronic rhinosinusitis recalcitrant refractory therapy-resistant bacteriophages phages

Übergeordnetes Werk:	In: Antibiotics - MDPI AG, 2013, 10(2021), 6, p 675
Übergeordnetes Werk:	volume:10 ; year:2021 ; number:6, p 675

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/antibiotics10060675

Katalog-ID:	DOAJ053492684

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ053492684
003	DE-627
005	20240412175136.0
007	cr uuu---uuuuu
008	230227s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/antibiotics10060675 \|2 doi
035			\|a (DE-627)DOAJ053492684
035			\|a (DE-599)DOAJ5c8ae0598b6043bf8286587319467782
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RM1-950
100	0		\|a Saartje Uyttebroek \|e verfasserin \|4 aut
245	1	4	\|a The Potential Role of Bacteriophages in the Treatment of Recalcitrant Chronic Rhinosinusitis
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Chronic rhinosinusitis is a common condition affecting 5–12% of the general population worldwide. In a limited number of cases, the disease is recalcitrant to medical and surgical interventions, causing a major impact on physical, social and emotional well-being and increasing pressure on healthcare systems. Biofilm formation and dysbiosis caused by <i<Staphylococcus aureus</i< and <i<Pseudomonas aeruginosa</i< play a role in the pathogenesis of recalcitrant chronic rhinosinusitis. In these cases, a promising treatment alternative is the application of bacteriophages, which are viruses that infect and lyse bacteria. In this review, we appraise the evidence for the use of bacteriophages in the treatment of recalcitrant chronic rhinosinusitis. Additionally, (dis)advantages of bacteriophages and considerations for implementation of phage therapy in otorhinolaryngology practice will be discussed.
650		4	\|a chronic rhinosinusitis
650		4	\|a recalcitrant
650		4	\|a refractory
650		4	\|a therapy-resistant
650		4	\|a bacteriophages
650		4	\|a phages
653		0	\|a Therapeutics. Pharmacology
700	0		\|a Jolien Onsea \|e verfasserin \|4 aut
700	0		\|a Willem-Jan Metsemakers \|e verfasserin \|4 aut
700	0		\|a Lieven Dupont \|e verfasserin \|4 aut
700	0		\|a David Devolder \|e verfasserin \|4 aut
700	0		\|a Jeroen Wagemans \|e verfasserin \|4 aut
700	0		\|a Rob Lavigne \|e verfasserin \|4 aut
700	0		\|a Isabel Spriet \|e verfasserin \|4 aut
700	0		\|a Laura Van Gerven \|e verfasserin \|4 aut
773	0	8	\|i In \|t Antibiotics \|d MDPI AG, 2013 \|g 10(2021), 6, p 675 \|w (DE-627)726120596 \|w (DE-600)2681345-2 \|x 20796382 \|7 nnns
773	1	8	\|g volume:10 \|g year:2021 \|g number:6, p 675
856	4	0	\|u https://doi.org/10.3390/antibiotics10060675 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/5c8ae0598b6043bf8286587319467782 \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/2079-6382/10/6/675 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2079-6382 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 10 \|j 2021 \|e 6, p 675

Indexfelder

author_variant	s u su j o jo w j m wjm l d ld d d dd j w jw r l rl i s is l v g lvg
matchkey_str	article:20796382:2021----::hptniloefatrohgsnhtetetfeactat
hierarchy_sort_str	2021
callnumber-subject-code	RM
publishDate	2021
allfields	10.3390/antibiotics10060675 doi (DE-627)DOAJ053492684 (DE-599)DOAJ5c8ae0598b6043bf8286587319467782 DE-627 ger DE-627 rakwb eng RM1-950 Saartje Uyttebroek verfasserin aut The Potential Role of Bacteriophages in the Treatment of Recalcitrant Chronic Rhinosinusitis 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Chronic rhinosinusitis is a common condition affecting 5–12% of the general population worldwide. In a limited number of cases, the disease is recalcitrant to medical and surgical interventions, causing a major impact on physical, social and emotional well-being and increasing pressure on healthcare systems. Biofilm formation and dysbiosis caused by <i<Staphylococcus aureus</i< and <i<Pseudomonas aeruginosa</i< play a role in the pathogenesis of recalcitrant chronic rhinosinusitis. In these cases, a promising treatment alternative is the application of bacteriophages, which are viruses that infect and lyse bacteria. In this review, we appraise the evidence for the use of bacteriophages in the treatment of recalcitrant chronic rhinosinusitis. Additionally, (dis)advantages of bacteriophages and considerations for implementation of phage therapy in otorhinolaryngology practice will be discussed. chronic rhinosinusitis recalcitrant refractory therapy-resistant bacteriophages phages Therapeutics. Pharmacology Jolien Onsea verfasserin aut Willem-Jan Metsemakers verfasserin aut Lieven Dupont verfasserin aut David Devolder verfasserin aut Jeroen Wagemans verfasserin aut Rob Lavigne verfasserin aut Isabel Spriet verfasserin aut Laura Van Gerven verfasserin aut In Antibiotics MDPI AG, 2013 10(2021), 6, p 675 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:10 year:2021 number:6, p 675 https://doi.org/10.3390/antibiotics10060675 kostenfrei https://doaj.org/article/5c8ae0598b6043bf8286587319467782 kostenfrei https://www.mdpi.com/2079-6382/10/6/675 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2021 6, p 675
spelling	10.3390/antibiotics10060675 doi (DE-627)DOAJ053492684 (DE-599)DOAJ5c8ae0598b6043bf8286587319467782 DE-627 ger DE-627 rakwb eng RM1-950 Saartje Uyttebroek verfasserin aut The Potential Role of Bacteriophages in the Treatment of Recalcitrant Chronic Rhinosinusitis 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Chronic rhinosinusitis is a common condition affecting 5–12% of the general population worldwide. In a limited number of cases, the disease is recalcitrant to medical and surgical interventions, causing a major impact on physical, social and emotional well-being and increasing pressure on healthcare systems. Biofilm formation and dysbiosis caused by <i<Staphylococcus aureus</i< and <i<Pseudomonas aeruginosa</i< play a role in the pathogenesis of recalcitrant chronic rhinosinusitis. In these cases, a promising treatment alternative is the application of bacteriophages, which are viruses that infect and lyse bacteria. In this review, we appraise the evidence for the use of bacteriophages in the treatment of recalcitrant chronic rhinosinusitis. Additionally, (dis)advantages of bacteriophages and considerations for implementation of phage therapy in otorhinolaryngology practice will be discussed. chronic rhinosinusitis recalcitrant refractory therapy-resistant bacteriophages phages Therapeutics. Pharmacology Jolien Onsea verfasserin aut Willem-Jan Metsemakers verfasserin aut Lieven Dupont verfasserin aut David Devolder verfasserin aut Jeroen Wagemans verfasserin aut Rob Lavigne verfasserin aut Isabel Spriet verfasserin aut Laura Van Gerven verfasserin aut In Antibiotics MDPI AG, 2013 10(2021), 6, p 675 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:10 year:2021 number:6, p 675 https://doi.org/10.3390/antibiotics10060675 kostenfrei https://doaj.org/article/5c8ae0598b6043bf8286587319467782 kostenfrei https://www.mdpi.com/2079-6382/10/6/675 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2021 6, p 675
allfields_unstemmed	10.3390/antibiotics10060675 doi (DE-627)DOAJ053492684 (DE-599)DOAJ5c8ae0598b6043bf8286587319467782 DE-627 ger DE-627 rakwb eng RM1-950 Saartje Uyttebroek verfasserin aut The Potential Role of Bacteriophages in the Treatment of Recalcitrant Chronic Rhinosinusitis 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Chronic rhinosinusitis is a common condition affecting 5–12% of the general population worldwide. In a limited number of cases, the disease is recalcitrant to medical and surgical interventions, causing a major impact on physical, social and emotional well-being and increasing pressure on healthcare systems. Biofilm formation and dysbiosis caused by <i<Staphylococcus aureus</i< and <i<Pseudomonas aeruginosa</i< play a role in the pathogenesis of recalcitrant chronic rhinosinusitis. In these cases, a promising treatment alternative is the application of bacteriophages, which are viruses that infect and lyse bacteria. In this review, we appraise the evidence for the use of bacteriophages in the treatment of recalcitrant chronic rhinosinusitis. Additionally, (dis)advantages of bacteriophages and considerations for implementation of phage therapy in otorhinolaryngology practice will be discussed. chronic rhinosinusitis recalcitrant refractory therapy-resistant bacteriophages phages Therapeutics. Pharmacology Jolien Onsea verfasserin aut Willem-Jan Metsemakers verfasserin aut Lieven Dupont verfasserin aut David Devolder verfasserin aut Jeroen Wagemans verfasserin aut Rob Lavigne verfasserin aut Isabel Spriet verfasserin aut Laura Van Gerven verfasserin aut In Antibiotics MDPI AG, 2013 10(2021), 6, p 675 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:10 year:2021 number:6, p 675 https://doi.org/10.3390/antibiotics10060675 kostenfrei https://doaj.org/article/5c8ae0598b6043bf8286587319467782 kostenfrei https://www.mdpi.com/2079-6382/10/6/675 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2021 6, p 675
allfieldsGer	10.3390/antibiotics10060675 doi (DE-627)DOAJ053492684 (DE-599)DOAJ5c8ae0598b6043bf8286587319467782 DE-627 ger DE-627 rakwb eng RM1-950 Saartje Uyttebroek verfasserin aut The Potential Role of Bacteriophages in the Treatment of Recalcitrant Chronic Rhinosinusitis 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Chronic rhinosinusitis is a common condition affecting 5–12% of the general population worldwide. In a limited number of cases, the disease is recalcitrant to medical and surgical interventions, causing a major impact on physical, social and emotional well-being and increasing pressure on healthcare systems. Biofilm formation and dysbiosis caused by <i<Staphylococcus aureus</i< and <i<Pseudomonas aeruginosa</i< play a role in the pathogenesis of recalcitrant chronic rhinosinusitis. In these cases, a promising treatment alternative is the application of bacteriophages, which are viruses that infect and lyse bacteria. In this review, we appraise the evidence for the use of bacteriophages in the treatment of recalcitrant chronic rhinosinusitis. Additionally, (dis)advantages of bacteriophages and considerations for implementation of phage therapy in otorhinolaryngology practice will be discussed. chronic rhinosinusitis recalcitrant refractory therapy-resistant bacteriophages phages Therapeutics. Pharmacology Jolien Onsea verfasserin aut Willem-Jan Metsemakers verfasserin aut Lieven Dupont verfasserin aut David Devolder verfasserin aut Jeroen Wagemans verfasserin aut Rob Lavigne verfasserin aut Isabel Spriet verfasserin aut Laura Van Gerven verfasserin aut In Antibiotics MDPI AG, 2013 10(2021), 6, p 675 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:10 year:2021 number:6, p 675 https://doi.org/10.3390/antibiotics10060675 kostenfrei https://doaj.org/article/5c8ae0598b6043bf8286587319467782 kostenfrei https://www.mdpi.com/2079-6382/10/6/675 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2021 6, p 675
allfieldsSound	10.3390/antibiotics10060675 doi (DE-627)DOAJ053492684 (DE-599)DOAJ5c8ae0598b6043bf8286587319467782 DE-627 ger DE-627 rakwb eng RM1-950 Saartje Uyttebroek verfasserin aut The Potential Role of Bacteriophages in the Treatment of Recalcitrant Chronic Rhinosinusitis 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Chronic rhinosinusitis is a common condition affecting 5–12% of the general population worldwide. In a limited number of cases, the disease is recalcitrant to medical and surgical interventions, causing a major impact on physical, social and emotional well-being and increasing pressure on healthcare systems. Biofilm formation and dysbiosis caused by <i<Staphylococcus aureus</i< and <i<Pseudomonas aeruginosa</i< play a role in the pathogenesis of recalcitrant chronic rhinosinusitis. In these cases, a promising treatment alternative is the application of bacteriophages, which are viruses that infect and lyse bacteria. In this review, we appraise the evidence for the use of bacteriophages in the treatment of recalcitrant chronic rhinosinusitis. Additionally, (dis)advantages of bacteriophages and considerations for implementation of phage therapy in otorhinolaryngology practice will be discussed. chronic rhinosinusitis recalcitrant refractory therapy-resistant bacteriophages phages Therapeutics. Pharmacology Jolien Onsea verfasserin aut Willem-Jan Metsemakers verfasserin aut Lieven Dupont verfasserin aut David Devolder verfasserin aut Jeroen Wagemans verfasserin aut Rob Lavigne verfasserin aut Isabel Spriet verfasserin aut Laura Van Gerven verfasserin aut In Antibiotics MDPI AG, 2013 10(2021), 6, p 675 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:10 year:2021 number:6, p 675 https://doi.org/10.3390/antibiotics10060675 kostenfrei https://doaj.org/article/5c8ae0598b6043bf8286587319467782 kostenfrei https://www.mdpi.com/2079-6382/10/6/675 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2021 6, p 675
language	English
source	In Antibiotics 10(2021), 6, p 675 volume:10 year:2021 number:6, p 675
sourceStr	In Antibiotics 10(2021), 6, p 675 volume:10 year:2021 number:6, p 675
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	chronic rhinosinusitis recalcitrant refractory therapy-resistant bacteriophages phages Therapeutics. Pharmacology
isfreeaccess_bool	true
container_title	Antibiotics
authorswithroles_txt_mv	Saartje Uyttebroek @@aut@@ Jolien Onsea @@aut@@ Willem-Jan Metsemakers @@aut@@ Lieven Dupont @@aut@@ David Devolder @@aut@@ Jeroen Wagemans @@aut@@ Rob Lavigne @@aut@@ Isabel Spriet @@aut@@ Laura Van Gerven @@aut@@
publishDateDaySort_date	2021-01-01T00:00:00Z
hierarchy_top_id	726120596
id	DOAJ053492684
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ053492684</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240412175136.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/antibiotics10060675</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ053492684</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5c8ae0598b6043bf8286587319467782</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Saartje Uyttebroek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Potential Role of Bacteriophages in the Treatment of Recalcitrant Chronic Rhinosinusitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Chronic rhinosinusitis is a common condition affecting 5–12% of the general population worldwide. In a limited number of cases, the disease is recalcitrant to medical and surgical interventions, causing a major impact on physical, social and emotional well-being and increasing pressure on healthcare systems. Biofilm formation and dysbiosis caused by <i<Staphylococcus aureus</i< and <i<Pseudomonas aeruginosa</i< play a role in the pathogenesis of recalcitrant chronic rhinosinusitis. In these cases, a promising treatment alternative is the application of bacteriophages, which are viruses that infect and lyse bacteria. In this review, we appraise the evidence for the use of bacteriophages in the treatment of recalcitrant chronic rhinosinusitis. Additionally, (dis)advantages of bacteriophages and considerations for implementation of phage therapy in otorhinolaryngology practice will be discussed.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chronic rhinosinusitis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">recalcitrant</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">refractory</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">therapy-resistant</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">bacteriophages</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">phages</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jolien Onsea</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Willem-Jan Metsemakers</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lieven Dupont</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David Devolder</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jeroen Wagemans</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rob Lavigne</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Isabel Spriet</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Laura Van Gerven</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Antibiotics</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">10(2021), 6, p 675</subfield><subfield code="w">(DE-627)726120596</subfield><subfield code="w">(DE-600)2681345-2</subfield><subfield code="x">20796382</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:6, p 675</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/antibiotics10060675</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5c8ae0598b6043bf8286587319467782</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2079-6382/10/6/675</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2079-6382</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2021</subfield><subfield code="e">6, p 675</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Saartje Uyttebroek
spellingShingle	Saartje Uyttebroek misc RM1-950 misc chronic rhinosinusitis misc recalcitrant misc refractory misc therapy-resistant misc bacteriophages misc phages misc Therapeutics. Pharmacology The Potential Role of Bacteriophages in the Treatment of Recalcitrant Chronic Rhinosinusitis
authorStr	Saartje Uyttebroek
ppnlink_with_tag_str_mv	@@773@@(DE-627)726120596
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RM1-950
illustrated	Not Illustrated
issn	20796382
topic_title	RM1-950 The Potential Role of Bacteriophages in the Treatment of Recalcitrant Chronic Rhinosinusitis chronic rhinosinusitis recalcitrant refractory therapy-resistant bacteriophages phages
topic	misc RM1-950 misc chronic rhinosinusitis misc recalcitrant misc refractory misc therapy-resistant misc bacteriophages misc phages misc Therapeutics. Pharmacology
topic_unstemmed	misc RM1-950 misc chronic rhinosinusitis misc recalcitrant misc refractory misc therapy-resistant misc bacteriophages misc phages misc Therapeutics. Pharmacology
topic_browse	misc RM1-950 misc chronic rhinosinusitis misc recalcitrant misc refractory misc therapy-resistant misc bacteriophages misc phages misc Therapeutics. Pharmacology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Antibiotics
hierarchy_parent_id	726120596
hierarchy_top_title	Antibiotics
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)726120596 (DE-600)2681345-2
title	The Potential Role of Bacteriophages in the Treatment of Recalcitrant Chronic Rhinosinusitis
ctrlnum	(DE-627)DOAJ053492684 (DE-599)DOAJ5c8ae0598b6043bf8286587319467782
title_full	The Potential Role of Bacteriophages in the Treatment of Recalcitrant Chronic Rhinosinusitis
author_sort	Saartje Uyttebroek
journal	Antibiotics
journalStr	Antibiotics
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2021
contenttype_str_mv	txt
author_browse	Saartje Uyttebroek Jolien Onsea Willem-Jan Metsemakers Lieven Dupont David Devolder Jeroen Wagemans Rob Lavigne Isabel Spriet Laura Van Gerven
container_volume	10
class	RM1-950
format_se	Elektronische Aufsätze
author-letter	Saartje Uyttebroek
doi_str_mv	10.3390/antibiotics10060675
author2-role	verfasserin
title_sort	potential role of bacteriophages in the treatment of recalcitrant chronic rhinosinusitis
callnumber	RM1-950
title_auth	The Potential Role of Bacteriophages in the Treatment of Recalcitrant Chronic Rhinosinusitis
abstract	Chronic rhinosinusitis is a common condition affecting 5–12% of the general population worldwide. In a limited number of cases, the disease is recalcitrant to medical and surgical interventions, causing a major impact on physical, social and emotional well-being and increasing pressure on healthcare systems. Biofilm formation and dysbiosis caused by <i<Staphylococcus aureus</i< and <i<Pseudomonas aeruginosa</i< play a role in the pathogenesis of recalcitrant chronic rhinosinusitis. In these cases, a promising treatment alternative is the application of bacteriophages, which are viruses that infect and lyse bacteria. In this review, we appraise the evidence for the use of bacteriophages in the treatment of recalcitrant chronic rhinosinusitis. Additionally, (dis)advantages of bacteriophages and considerations for implementation of phage therapy in otorhinolaryngology practice will be discussed.
abstractGer	Chronic rhinosinusitis is a common condition affecting 5–12% of the general population worldwide. In a limited number of cases, the disease is recalcitrant to medical and surgical interventions, causing a major impact on physical, social and emotional well-being and increasing pressure on healthcare systems. Biofilm formation and dysbiosis caused by <i<Staphylococcus aureus</i< and <i<Pseudomonas aeruginosa</i< play a role in the pathogenesis of recalcitrant chronic rhinosinusitis. In these cases, a promising treatment alternative is the application of bacteriophages, which are viruses that infect and lyse bacteria. In this review, we appraise the evidence for the use of bacteriophages in the treatment of recalcitrant chronic rhinosinusitis. Additionally, (dis)advantages of bacteriophages and considerations for implementation of phage therapy in otorhinolaryngology practice will be discussed.
abstract_unstemmed	Chronic rhinosinusitis is a common condition affecting 5–12% of the general population worldwide. In a limited number of cases, the disease is recalcitrant to medical and surgical interventions, causing a major impact on physical, social and emotional well-being and increasing pressure on healthcare systems. Biofilm formation and dysbiosis caused by <i<Staphylococcus aureus</i< and <i<Pseudomonas aeruginosa</i< play a role in the pathogenesis of recalcitrant chronic rhinosinusitis. In these cases, a promising treatment alternative is the application of bacteriophages, which are viruses that infect and lyse bacteria. In this review, we appraise the evidence for the use of bacteriophages in the treatment of recalcitrant chronic rhinosinusitis. Additionally, (dis)advantages of bacteriophages and considerations for implementation of phage therapy in otorhinolaryngology practice will be discussed.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	6, p 675
title_short	The Potential Role of Bacteriophages in the Treatment of Recalcitrant Chronic Rhinosinusitis
url	https://doi.org/10.3390/antibiotics10060675 https://doaj.org/article/5c8ae0598b6043bf8286587319467782 https://www.mdpi.com/2079-6382/10/6/675 https://doaj.org/toc/2079-6382
remote_bool	true
author2	Jolien Onsea Willem-Jan Metsemakers Lieven Dupont David Devolder Jeroen Wagemans Rob Lavigne Isabel Spriet Laura Van Gerven
author2Str	Jolien Onsea Willem-Jan Metsemakers Lieven Dupont David Devolder Jeroen Wagemans Rob Lavigne Isabel Spriet Laura Van Gerven
ppnlink	726120596
callnumber-subject	RM - Therapeutics and Pharmacology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/antibiotics10060675
callnumber-a	RM1-950
up_date	2024-07-03T17:57:33.399Z
_version_	1803581604131504128
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ053492684</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240412175136.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/antibiotics10060675</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ053492684</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5c8ae0598b6043bf8286587319467782</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Saartje Uyttebroek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Potential Role of Bacteriophages in the Treatment of Recalcitrant Chronic Rhinosinusitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Chronic rhinosinusitis is a common condition affecting 5–12% of the general population worldwide. In a limited number of cases, the disease is recalcitrant to medical and surgical interventions, causing a major impact on physical, social and emotional well-being and increasing pressure on healthcare systems. Biofilm formation and dysbiosis caused by <i<Staphylococcus aureus</i< and <i<Pseudomonas aeruginosa</i< play a role in the pathogenesis of recalcitrant chronic rhinosinusitis. In these cases, a promising treatment alternative is the application of bacteriophages, which are viruses that infect and lyse bacteria. In this review, we appraise the evidence for the use of bacteriophages in the treatment of recalcitrant chronic rhinosinusitis. Additionally, (dis)advantages of bacteriophages and considerations for implementation of phage therapy in otorhinolaryngology practice will be discussed.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chronic rhinosinusitis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">recalcitrant</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">refractory</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">therapy-resistant</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">bacteriophages</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">phages</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jolien Onsea</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Willem-Jan Metsemakers</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lieven Dupont</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David Devolder</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jeroen Wagemans</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rob Lavigne</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Isabel Spriet</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Laura Van Gerven</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Antibiotics</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">10(2021), 6, p 675</subfield><subfield code="w">(DE-627)726120596</subfield><subfield code="w">(DE-600)2681345-2</subfield><subfield code="x">20796382</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:6, p 675</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/antibiotics10060675</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5c8ae0598b6043bf8286587319467782</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2079-6382/10/6/675</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2079-6382</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2021</subfield><subfield code="e">6, p 675</subfield></datafield></record></collection>
score	7.400346

Nicht das Richtige dabei?

Schreiben Sie uns!

The Potential Role of Bacteriophages in the Treatment of Recalcitrant Chronic Rhinosinusitis

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?